Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05170126

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

ZEPOSIA® (Ozanimod) Pregnancy Registry: A Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,182 (estimated)
Sponsor
Bristol-Myers Squibb · Industry
Sex
Female
Age
Healthy volunteers

Summary

The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.

Conditions

Timeline

Start date
2022-07-15
Primary completion
2032-06-30
Completion
2032-06-30
First posted
2021-12-27
Last updated
2025-11-20

Locations

3 sites across 2 countries: United States, Germany

Source: ClinicalTrials.gov record NCT05170126. Inclusion in this directory is not an endorsement.

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring (NCT05170126) · Clinical Trials Directory